Three phase 3 clinical trials investigating combinations of anti-TIGIT and anti-PD-L1 or anti-PD-1 in patients with NSCLC are currently underway (NCT04738487, NCT04746924, and NCT04736173). Here, TIGIT is linked to non-small cell lung carcinoma.